• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

限制平均生存时间以改善癌症随机试验和观察性研究证据的交流。

Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies.

机构信息

Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

出版信息

Eur Urol. 2019 Aug;76(2):137-139. doi: 10.1016/j.eururo.2019.04.002. Epub 2019 Apr 26.

DOI:10.1016/j.eururo.2019.04.002
PMID:31031048
Abstract

Hazard ratios (HRs) are frequently misinterpreted. We describe an easily estimated complementary measure, the difference in restricted mean survival time (RMST), that requires fewer assumptions than the HR and is more readily interpretable. Reporting RMST-based measures may benefit shared decision-making.

摘要

风险比（HR）经常被误解。我们描述了一种易于估计的补充衡量指标，即受限平均生存时间（RMST）的差异，它比 HR 假设更少，更易于解释。报告基于 RMST 的衡量指标可能有利于共同决策。

相似文献

1
Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies.限制平均生存时间以改善癌症随机试验和观察性研究证据的交流。
Eur Urol. 2019 Aug;76(2):137-139. doi: 10.1016/j.eururo.2019.04.002. Epub 2019 Apr 26.
2
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.免疫检查点抑制剂治疗癌症的临床试验中通过受限平均生存时间衡量的治疗效果。
Ann Oncol. 2018 May 1;29(5):1320-1324. doi: 10.1093/annonc/mdy075.
3
Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.在具有事件发生时间终点的优效性试验中，受限平均生存时间与风险比的比较。
Pharm Stat. 2018 May;17(3):202-213. doi: 10.1002/pst.1846. Epub 2017 Dec 28.
4
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.肿瘤学随机对照试验中风险比和受限平均生存时间比测量的治疗效果比较。
J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16.
5
[Application of restricted mean survival time in clinical follow-up study].受限平均生存时间在临床随访研究中的应用
Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Feb 10;40(2):247-250. doi: 10.3760/cma.j.issn.0254-6450.2019.02.023.
6
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
7
Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.限制平均生存时间的用途和局限性：2 型糖尿病心血管结局和死亡率试验的实例说明。
Ann Intern Med. 2020 Apr 21;172(8):541-552. doi: 10.7326/M19-3286. Epub 2020 Mar 24.
8
Design of non-inferiority randomized trials using the difference in restricted mean survival times.基于受限平均生存时间差值的非劣效性随机临床试验设计。
Clin Trials. 2018 Oct;15(5):499-508. doi: 10.1177/1740774518792259. Epub 2018 Aug 3.
9
The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.限制平均生存时间在 HIV/AIDS 临床试验中作为治疗措施的应用：ACTG A5257 试验再分析。
J Acquir Immune Defic Syndr. 2019 May 1;81(1):44-51. doi: 10.1097/QAI.0000000000001978.
10
Adjusting for covariates in analysis based on restricted mean survival times.基于限制平均生存时间的分析中调整协变量。
Pharm Stat. 2022 Jan;21(1):38-54. doi: 10.1002/pst.2151. Epub 2021 Jul 6.

引用本文的文献

1
Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.阿帕鲁胺在转移性去势敏感性前列腺癌中的肿瘤负荷及异质性治疗效果
Cancer. 2025 Apr 1;131(7):e35819. doi: 10.1002/cncr.35819.
2
Individualized survival prediction and surgery recommendation for patients with glioblastoma.胶质母细胞瘤患者的个性化生存预测与手术建议
Front Med (Lausanne). 2024 May 9;11:1330907. doi: 10.3389/fmed.2024.1330907. eCollection 2024.
3
Survival After Implementation of a Decision Support Tool to Facilitate Evidence-Based Cancer Treatment.
实施决策支持工具以促进基于证据的癌症治疗后的生存情况。
JCO Clin Cancer Inform. 2023 Jun;7:e2300001. doi: 10.1200/CCI.23.00001.
4
Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system.安全网医疗体系中结肠癌患者辅助化疗开始时间与死亡率的关系。
BMC Cancer. 2022 May 31;22(1):593. doi: 10.1186/s12885-022-09688-w.
5
Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer.基尼平均差和术前化疗后晚期乳腺癌淋巴结量子分类的长期预后价值。
Sci Rep. 2022 Feb 22;12(1):2983. doi: 10.1038/s41598-022-07078-7.
6
Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times.II/III期乳腺癌新辅助化疗后的淋巴结比率：用受限平均生存时间的基尼平均差衡量的预后价值
Cancer Inform. 2021 Oct 12;20:11769351211051675. doi: 10.1177/11769351211051675. eCollection 2021.
7
Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort Study.老年前列腺癌患者对治疗指南的依从性及其相关生存率：一项前瞻性多中心队列研究
Cancers (Basel). 2021 Sep 18;13(18):4694. doi: 10.3390/cancers13184694.
8
Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.多状态模型框架中替代和临床事件时间结局的反事实中介分析在随机对照试验中。
Pharm Stat. 2022 Jan;21(1):163-175. doi: 10.1002/pst.2159. Epub 2021 Aug 4.
9
Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.随机临床试验中受限平均生存时间序贯分析的统计学考量
Stat Biopharm Res. 2021;13(2):210-218. doi: 10.1080/19466315.2020.1816491. Epub 2020 Oct 9.
10
Psychotropic medication use during pregnancy and gestational age at delivery.孕期使用精神药物与分娩时的胎龄。
Ann Epidemiol. 2021 Jan;53:34-41.e2. doi: 10.1016/j.annepidem.2020.08.010. Epub 2020 Aug 22.